Support Local Journalism. Join the Cleveland Scene Press Club.

Friday, September 3, 2021

Bipartisan Pair of State Senators Introduce Bill to Cap Insulin Costs

Posted By on Fri, Sep 3, 2021 at 11:00 AM

click to enlarge A bill to price cap insulin costs was introduced by the pair - OFFICIAL STATEHOUSE PHOTOS
  • Official statehouse photos
  • A bill to price cap insulin costs was introduced by the pair

A bipartisan pair of state Senators introduced legislation Monday to cap the prices health insurers can charge people with diabetes for their insulin.

Senate Bill 220, if passed, would prohibit insurers from charging more than $35 for a 30-day supply of insulin. The bill, less than 100 words in length, could save thousands annually for a portion of Ohio’s 1 million people living with diabetes who rely on insulin to survive and manage their blood sugar.



Costs vary widely for insulin depending on one’s health insurance. A patient on Lantus, an insulin brand, could pay anywhere between $400 to $500 a month, according to Antonio Ciaccia, CEO of 46Brooklyn, which tracks drug prices. Similar drugs like Novolog or Humalog cost $300 to $350 per month.

Research from 2019 in the Journal of American Medicine found insulin costs had tripled over the prior decade and out-of-pocket costs doubled. This resulted in one in four sampled diabetics reporting underusing insulin — a dangerous practice.

“Insulin is a life-saving, essential medicine, and most patients cannot act as price-sensitive buyers,” the researchers wrote. “Regulators and the medical community need to intervene to ensure that insulin is available to patients who need it.”

Sens. Hearcel Craig, D-Columbus, and Nathan Manning, R-North Ridgeville, introduced SB 220. Craig declined an interview but issued a statement through a spokeswoman.

“Currently, too many Ohioans ration their insulin to save money, a practice that can be fatal. Capping the cost of insulin at $35 for a thirty-day supply helps make sure that they can afford this essential medication,” Craig said in a statement.

House Democrats introduced a similar version of the proposal during the prior legislative session, which stalled out after a single hearing in the Republican-controlled House Health Committee. Sponsorship from Manning, chairman of the Senate Judiciary Committee, likely gives the bill a better chance in the supermajority Republican Senate. Manning, through an aide, deferred comment to Craig.

Lawmakers are set to reconvene in September.

Allegations of impropriety trail insulin’s high costs. In 2019, Heritage Pharmaceuticals paid a $7 million penalty in an agreement with the U.S. Department of Justice after it was accused of price fixing and bid rigging around Glyburide, a diabetes drug. Reuters reported last month a judge denied a motion to dismiss a 2017 lawsuit brought against drug manufacturers and pharmacy benefit managers alleging that insulin drug prices have been inflated by kickbacks, in the form of rebates and administrative fees, paid by drugmakers to PBMs in exchange for favorable placement on PBMs’ drug formularies.

Originally published by the Ohio Capital Journal. Republished here with permission.

Tags: , , ,

We welcome readers to submit letters regarding articles and content in Cleveland Scene. Letters should be a minimum of 150 words, refer to content that has appeared on Cleveland Scene, and must include the writer's full name, address, and phone number for verification purposes. No attachments will be considered. Writers of letters selected for publication will be notified via email. Letters may be edited and shortened for space.

Email us at news@clevescene.com.

Support Local Journalism.
Join the Cleveland Scene Press Club


Local journalism is information. Information is power. And we believe everyone deserves access to accurate independent coverage of their community and state. Our readers helped us continue this coverage in 2020, and we are so grateful for the support.


Help us keep this coverage going in 2021. Whether it's a one-time acknowledgement of this article or an ongoing membership pledge, your support goes to local-based reporting from our small but mighty team.


Join the Cleveland Scene Press Club for as little as $5 a month.

Read the Digital Print Issue

January 5, 2022

View more issues

Newsletters

Never miss a beat

Sign Up Now

Subscribe now to get the latest news delivered right to your inbox.

Calendar

© 2022 Cleveland Scene: 737 Bolivar Rd., Suite 4100, Cleveland, OH 44115, (216) 505-8199
Logos and trademarks on this site are property of their respective owners.


Website powered by Foundation